1 / 11

The B Cell Company

La Jolla Pharmaceutical Company. The B Cell Company. Lupus Stroke MI DVT Xenotransplantation Myasthenia Gravis Rh Hemolytic Disease. Disease-causing antibodies. B cells. Rheumatoid Arthritis Diabetes Multiple Sclerosis Scleroderma. T cells. Two types of autoimmune diseases.

ronat
Download Presentation

The B Cell Company

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. La Jolla Pharmaceutical Company The B Cell Company

  2. Lupus Stroke MI DVT Xenotransplantation Myasthenia Gravis Rh Hemolytic Disease Disease-causing antibodies B cells Rheumatoid Arthritis Diabetes Multiple Sclerosis Scleroderma T cells Two types of autoimmune diseases

  3. Stroke Heart attackDeep vein thrombosis 500,000 Lupus1,000,000 Xenotransplantation200,000+ Rh HemolyticDisease40,000 Myasthenia Gravis40,000 Market opportunity $4 billion

  4. LJP 394 - Lupus LJP 920 - Xenotransplantation LJP 993 - Thrombosis Product pipeline

  5. Lupus Antibody-mediated thrombosis Xenotransplantation Contract manufacturing

  6. Current therapy problems Click Photo to play video • Steroids • Diabetes, hypertension, cataracts, osteoporosis and psychosis • Lead to severe infections • Chemotherapy • Weight loss, nausea and sterility • Increased risk of malignancies • Lead to severe infections Daniel J. Wallace, M.D.Cedars-Sinai UCLA

  7. Antibody level Flares Steroids Antibodylevels Antibody level 10% Flares Steroids Time Reducing antibody rises prevents flares Treatment in response to: Patients with flares: 80% Disease H. Bootsma et al. The Lancet Feb. 1995

  8. Clinical trial sites Columbia Emory Harvard Johns Hopkins Stanford UCLA University of Chicago

  9. Xenotransplantation - acute & chronic rejection AnimalOrgan

  10. La Jolla Pharmaceutical Company The B Cell Company Click Escape to end

More Related